Cell Source, Inc. (CLCS)
USD 0.28
(-16.67%)
USD 0.28
(-16.67%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 195.17 Thousand USD | -52.38% |
| 2022 | 409.84 Thousand USD | 30.62% |
| 2021 | 313.76 Thousand USD | -30.63% |
| 2020 | 452.33 Thousand USD | 294.08% |
| 2019 | 114.78 Thousand USD | 74.46% |
| 2018 | 65.79 Thousand USD | -87.63% |
| 2017 | 531.67 Thousand USD | 151.86% |
| 2016 | 211.1 Thousand USD | -42.6% |
| 2015 | 367.76 Thousand USD | 198.74% |
| 2014 | 123.1 Thousand USD | 559.41% |
| 2013 | 18.66 Thousand USD | -15.34% |
| 2012 | 22.05 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 82.58 Thousand USD | -57.68% |
| 2024 Q2 | 429.76 Thousand USD | 420.37% |
| 2023 Q4 | 195.17 Thousand USD | -21.42% |
| 2023 Q2 | 362.32 Thousand USD | 55.89% |
| 2023 Q1 | 232.42 Thousand USD | -43.29% |
| 2023 Q3 | 248.35 Thousand USD | -31.46% |
| 2023 FY | 195.17 Thousand USD | -52.38% |
| 2022 Q2 | 44.64 Thousand USD | -83.87% |
| 2022 Q3 | 360.61 Thousand USD | 707.82% |
| 2022 FY | 409.84 Thousand USD | 30.62% |
| 2022 Q1 | 276.8 Thousand USD | -11.78% |
| 2022 Q4 | 409.84 Thousand USD | 13.65% |
| 2021 Q4 | 313.76 Thousand USD | -63.54% |
| 2021 Q3 | 860.67 Thousand USD | 178.95% |
| 2021 Q2 | 308.53 Thousand USD | -3.22% |
| 2021 FY | 313.76 Thousand USD | -30.63% |
| 2021 Q1 | 318.8 Thousand USD | -29.52% |
| 2020 Q4 | 452.33 Thousand USD | 115.06% |
| 2020 Q2 | 82.29 Thousand USD | -37.5% |
| 2020 Q3 | 210.32 Thousand USD | 155.59% |
| 2020 FY | 452.33 Thousand USD | 294.08% |
| 2020 Q1 | 131.66 Thousand USD | 14.7% |
| 2019 Q2 | 79.63 Thousand USD | 35.21% |
| 2019 FY | 114.78 Thousand USD | 74.46% |
| 2019 Q1 | 58.89 Thousand USD | -10.48% |
| 2019 Q4 | 114.78 Thousand USD | 48.21% |
| 2019 Q3 | 77.44 Thousand USD | -2.75% |
| 2018 Q3 | 141.7 Thousand USD | 7.73% |
| 2018 FY | 65.79 Thousand USD | -87.63% |
| 2018 Q1 | 410.86 Thousand USD | -22.72% |
| 2018 Q2 | 131.54 Thousand USD | -67.98% |
| 2018 Q4 | 65.79 Thousand USD | -53.57% |
| 2017 FY | 531.67 Thousand USD | 151.86% |
| 2017 Q1 | 66.6 Thousand USD | -68.45% |
| 2017 Q2 | 228.33 Thousand USD | 242.81% |
| 2017 Q3 | 150.11 Thousand USD | -34.26% |
| 2017 Q4 | 531.67 Thousand USD | 254.18% |
| 2016 Q2 | 248.63 Thousand USD | -38.97% |
| 2016 FY | 211.1 Thousand USD | -42.6% |
| 2016 Q3 | 282.38 Thousand USD | 13.57% |
| 2016 Q4 | 211.1 Thousand USD | -25.24% |
| 2016 Q1 | 407.42 Thousand USD | 10.78% |
| 2015 Q3 | 311.55 Thousand USD | -2.48% |
| 2015 Q2 | 319.46 Thousand USD | -21.54% |
| 2015 Q1 | 407.16 Thousand USD | 230.75% |
| 2015 FY | 367.76 Thousand USD | 198.74% |
| 2015 Q4 | 367.76 Thousand USD | 18.04% |
| 2014 Q4 | 123.1 Thousand USD | -54.91% |
| 2014 FY | 123.1 Thousand USD | 559.41% |
| 2014 Q2 | 1.08 Million USD | 50385.73% |
| 2014 Q1 | 2152.00 USD | -88.47% |
| 2014 Q3 | 272.99 Thousand USD | -74.87% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | 18.66 Thousand USD | 49.56% |
| 2013 FY | 18.66 Thousand USD | -15.34% |
| 2013 Q3 | 12.48 Thousand USD | 0.0% |
| 2012 FY | 22.05 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -8348.961% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 90.033% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 98.151% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 64.651% |
| Rebus Holdings, Inc. | 5000.00 USD | -3803.42% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.85% |
| Qrons Inc. | 420.00 USD | -46369.286% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 74.674% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.302% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 59.387% |
| Skye Bioscience, Inc. | 11.94 Million USD | 98.365% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.498% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 97.297% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -155.613% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.818% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 86.371% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -169.704% |
| Mesoblast Limited | 667.9 Million USD | 99.971% |
| Marizyme, Inc. | 22.01 Million USD | 99.113% |
| Genus plc | 1.02 Billion USD | 99.981% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 85.632% |
| Pharming Group N.V. | 462.85 Million USD | 99.958% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 94.109% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 60.891% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 68.872% |
| ContraFect Corporation | 20.67 Million USD | 99.056% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 50.003% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 48.932% |
| IMV Inc. | 31.33 Million USD | 99.377% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 95.293% |
| MultiCell Technologies, Inc. | 126.22 USD | -154527.634% |
| ONE Bio Corp. | 70.08 Million USD | 99.722% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 79.23% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.848% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 54.792% |
| Q BioMed Inc. | 3.51 Million USD | 94.448% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.445% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 25.301% |
| Biomind Labs Inc. | 73.81 Thousand USD | -164.391% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.956% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 86.529% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.35% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 92.893% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 71.611% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 92.503% |
| GB Sciences, Inc. | 103.44 Thousand USD | -88.677% |
| Alpha Cognition Inc. | 2.45 Million USD | 92.041% |
| HST Global, Inc. | 1526.00 USD | -12689.712% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 80.245% |
| Halberd Corporation | 10.13 Thousand USD | -1826.473% |
| Enzolytics Inc. | 361.7 Million USD | 99.946% |
| Agentix Corp. | 261.39 Thousand USD | 25.334% |
| Resverlogix Corp. | 8.11 Million USD | 97.595% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 89.607% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.996% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.591% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 69.488% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -756.727% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 97.819% |
| AVAX Technologies, Inc. | 7.37 Million USD | 97.354% |
| Zenith Capital Corp. | 7410.00 USD | -2533.887% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.994% |
| Ember Therapeutics, Inc. | 184.00 USD | -105971.196% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 39.351% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 25.326% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 78.968% |
| Kadimastem Ltd | 2.3 Million USD | 91.529% |
| Helix BioMedix, Inc. | 3.02 Million USD | 93.548% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.63% |
| BioStem Technologies, Inc. | 14.56 Million USD | 98.66% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -241.842% |
| LadRx Corporation | 2.3 Million USD | 91.543% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 44.807% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 44.807% |
| NovAccess Global Inc. | 62.24 Thousand USD | -213.538% |
| Affymax, Inc. | 7.44 Million USD | 97.378% |
| Itoco Inc. | 1.4 Million USD | 86.06% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -104.032% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -84.124% |
| Mobile Lads Corp. | 52.00 USD | -375228.846% |
| CytoDyn Inc. | 11.13 Million USD | 98.247% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -36.51% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -991.56% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 49.368% |
| SYBLEU INC | 330.46 Thousand USD | 40.941% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 52.33% |
| International Stem Cell Corporation | 5.39 Million USD | 96.379% |
| Bioxytran, Inc. | 137.63 Thousand USD | -41.8% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 98.699% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 98.823% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -147.052% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 77.428% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 97.404% |
| Neutra Corp. | 2851.00 USD | -6745.703% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.398% |
| PureTech Health plc | 693.97 Million USD | 99.972% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 97.582% |
| IXICO plc | 15.84 Million USD | 98.768% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 97.643% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.811% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.942% |